AstraZeneca PLC Files 6-K Report
Ticker: AZN · Form: 6-K · Filed: Dec 1, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.25 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-issuer, regulatory-update
Related Tickers: AZN
TL;DR
AZN filed a 6-K, standard foreign issuer report, confirming 20-F filings.
AI Summary
AstraZeneca PLC filed a Form 6-K on December 1, 2025, reporting as a foreign issuer. The filing indicates that the company is submitting its report under the 1934 Securities Exchange Act and will file annual reports under Form 20-F. The company's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Why It Matters
This filing is a routine report for foreign issuers, providing an update on the company's status and reporting requirements to the SEC.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign issuer and does not contain new material financial or operational information.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- 001-11960 (company) — Commission File Number
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (company) — Company address
- 1934 Act (company) — Securities Exchange Act
- Form 20-F (company) — Annual report form
- Form 6-K (company) — Report type
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the registrant has made or is required to make public pursuant to the laws of its home country or foreign stock exchange, or that it has distributed or is required to distribute to its security holders.
Which annual report form does AstraZeneca PLC indicate it will file?
AstraZeneca PLC indicates it will file annual reports under cover of Form 20-F.
What is AstraZeneca PLC's filing date for this report?
The filing date for this Form 6-K is December 1, 2025.
Where are AstraZeneca PLC's principal executive offices located?
AstraZeneca PLC's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
What is the Commission File Number for AstraZeneca PLC?
The Commission File Number for AstraZeneca PLC is 001-11960.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 14.7 · Accepted 2025-12-01 11:40:48
Key Financial Figures
- $0.25 — s is 1,550,725,869 ordinary shares of US$0.25. No shares are held in Treasury. Theref
Filing Documents
- a6944j.htm (6-K) — 19KB
- 0001654954-25-013567.txt ( ) — 20KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date:  01 December 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary